Pi-Cardia Closes a $27 Million Financing led by Sofinnova Partners to Continue Clinical Trials With Its Leaflex(TM) Aortic Valve Technology

REHOVOT, Israel, April 20, 2020 -- (Healthcare Sales & Marketing Network) -- Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today it has closed a $27 million rou... Devices, Interventional, Cardiology, Venture Capital Pi-Cardia, Leaflex Performer, Leaflex, heart valve calcification
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news